339 related articles for article (PubMed ID: 15637459)
1. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
[TBL] [Abstract][Full Text] [Related]
2. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
[TBL] [Abstract][Full Text] [Related]
4. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
5. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
Ueshima K; Oba K; Yasuno S; Fujimoto A; Sato T; Fukiyama K; Azuma J; Ogihara T; Saruta T; Nakao K;
Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
8. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
[TBL] [Abstract][Full Text] [Related]
9. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
London G; Schmieder R; Calvo C; Asmar R
Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
[TBL] [Abstract][Full Text] [Related]
10. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Saruta T; Hayashi K; Ogihara T; Nakao K; Fukui T; Fukiyama K;
Hypertens Res; 2009 Jun; 32(6):505-12. PubMed ID: 19390535
[TBL] [Abstract][Full Text] [Related]
11. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.
Ecder T; Chapman AB; Brosnahan GM; Edelstein CL; Johnson AM; Schrier RW
Am J Kidney Dis; 2000 Mar; 35(3):427-32. PubMed ID: 10692268
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients.
Ishimitsu T; Kobayashi T; Honda T; Takahashi M; Minami J; Ohta S; Inada H; Yoshii M; Ono H; Matsuoka H
Hypertens Res; 2005 Apr; 28(4):351-9. PubMed ID: 16138566
[TBL] [Abstract][Full Text] [Related]
14. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
[TBL] [Abstract][Full Text] [Related]
15. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
Ogihara T; Nakao K; Fukui T; Fukiyama K; Ueshima K; Oba K; Sato T; Saruta T;
Hypertension; 2008 Feb; 51(2):393-8. PubMed ID: 18172059
[TBL] [Abstract][Full Text] [Related]
16. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
[TBL] [Abstract][Full Text] [Related]
17. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Fogari R; Corradi L; Zoppi A; Lazzari P; Mugellini A; Preti P; Rinaldi A
Am J Hypertens; 2007 Oct; 20(10):1092-6. PubMed ID: 17903693
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
[TBL] [Abstract][Full Text] [Related]
20. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
